Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13495858 | 0.82 | AKR1B1 (0.44) | HPGDAKR1B1BRD4CREBBPKDM4E | |
| SCHEMBL31040600 | 0.81 | MAOB (0.40) | TSHRAKR1B1L3MBTL1CES1SRD5A1 | |
| SCHEMBL11122122 | 0.81 | HPGD (0.42) | HPGDTSHRAKR1B1ALDH1A1 | |
| SCHEMBL6836824 | 0.78 | AKR1B1 (0.38) | TSHRAKR1B1CES1 | |
| SCHEMBL6836726 | 0.77 | KDM4E (0.53) | ALDH2ALDH3A1HPGDTSHRAKR1B1 | |
| SCHEMBL32673059 | 0.77 | TSHR (0.37) | HPGDTSHRAKR1B1KDM4ECES1 | |
| SCHEMBL28587199 | 0.77 | HPGD (0.41) | HPGDTSHRAKR1B1KDM4EALDH1A1 | |
| SCHEMBL16283615 | 0.77 | PTGS1 (0.41) | TSHRAKR1B1L3MBTL1ALDH1A1PARP1 | |
| SCHEMBL6838590 | 0.73 | ALDH2 (0.41) | ALDH2ALDH3A1HPGDTSHRKDM4E | |
| SCHEMBL6835962 | 0.73 | KDM4E (0.50) | ALDH2ALDH3A1HPGDTSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5639893-A | Process for producing octahydrocoumarins and same as a product of such process | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-06-17 | — | — | US | claimed |
| EP-0757989-A1 | A process for producing octahydrocoumarins and same as a product of such process | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | claimed |
| US-5300662-A | Process for producing coumarin and derivatives thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-04-05 | — | — | US | claimed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| EP-3765453-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112105610-A | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| EP-2061766-A2 | NOVEL COMPOUNDS | Torrent Pharmaceuticals Ltd (IN) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008149379-A2 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-12-11 | — | — | WO | disclosed |
| US-6756432-B2 | POLYBUTADIENE TYPE POLYMER WITH A 1-BENZOPYRAN, A 1-BENZO PYRAN-2-ONE OR A BENZOIN DERIVATIVE; MOLDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-06-29 | — | — | US | disclosed |
| US-20030153655-A1 | Polybutadiene composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-08-14 | — | — | US | disclosed |
| EP-0539181-B1 | Process for producing coumarin and derivatives thereof | SUMITOMO CHEMICAL CO (JP) | 1997-06-18 | — | — | EP | disclosed |
| US-5639893-A | Process for producing octahydrocoumarins and same as a product of such process | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0757989-A1 | A process for producing octahydrocoumarins and same as a product of such process | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| US-5300662-A | Process for producing coumarin and derivatives thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-04-05 | — | — | US | disclosed |
| EP-0539181-A1 | Process for producing coumarin and derivatives thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | CD274, PDCD1, PDCD1LG2 | ALDH2 1216/4885ALDH3A1 153/4885HPGD 1098/4885 |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | ALDH2 1216/4885ALDH3A1 153/4885HPGD 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.